Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort.

Idil EsenSuzanne ArendsBerit Dalsgaard NielsenPhilip TherkildsenIb HansenAnna van 't EndePeter HeeringaAnnemieke BootsEllen HaugeElisabeth Brouwer Yannick van Sleen

Published in: RMD open (2023)

Data from the GCA and PMR cohorts imply a metabolic dysregulation in treatment-naïve patients with GCA, but not in patients with PMR. Treatment with GCs led to the rise of comorbidities and an unhealthier metabolic profile, stressing the need for prednisone-sparing targeted treatment in these vulnerable patients.

Keyphrases

giant cell
ejection fraction
end stage renal disease
combination therapy
drug delivery
oxidative stress
machine learning
robot assisted
smoking cessation